GMED, US3795772082

Globus Medical stock expands its European imaging opportunity

Published on 09/28/2026 at 17:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Globus Medical stock now has EU and UK sales access for Excelsius3D after a September 3 CE mark. Q2 revenue reached USD 789.61 million, up 5.9 percent year over year.

GMED, US3795772082, Illustration mit AI erstellt.

Globus Medical (ISIN US3795772082) was trading at USD 74.58 on the NYSE on September 28, 2026, at 11:10 a.m. ET, up 0.07 percent in the session. The latest product milestone is Excelsius3D, which received CE marking for commercial sales in the European Union and United Kingdom on September 3, 2026, according to GlobeNewswire.

EU access expands the platform

Excelsius3D combines 3D cone-beam CT, 2D fluoroscopy and digital radiography in one mobile imaging system. Globus Medical said on September 3, 2026, that the product can operate independently or integrate with ExcelsiusGPS, extending the company’s robotic navigation ecosystem into two additional markets.

The commercial opportunity is strategic rather than immediately visible in the share-price snapshot. The CE mark removes a regulatory barrier for European sales, while the company’s stated risks include product demand, competition, regulatory compliance and the integration of acquired businesses, as disclosed in the same GlobeNewswire release.

Q2 revenue reaches USD 789.61 million

Globus Medical reported second-quarter 2026 revenue of USD 789.61 million, compared with USD 782.88 million consensus, and quarterly EPS of USD 1.34 versus USD 1.10 expected, according to MarketBeat in its September 4, 2026 report. Revenue was 5.9 percent higher than in the year-earlier quarter, and fiscal 2026 EPS guidance was USD 4.95-5.05.

That combination gives investors two measurable reference points: the company exceeded the quarterly revenue consensus by USD 6.73 million, while the reported EPS beat was USD 0.24. MarketBeat said the analyst consensus was Moderate Buy from 17 firms, with an average 12-month target of USD 101.77.

GMED trades below its yearly high

At USD 74.58 on September 28, 2026, GMED stood USD 26.82 below its 52-week high of USD 101.40 and USD 19.25 above its 52-week low of USD 55.33. The current market capitalization was USD 10.1 billion, and volume stood at 333,884 shares at 11:10 a.m. ET.

The market is therefore weighing a new European commercialization route against the slower-moving question of execution. The next checkpoints are adoption of Excelsius3D, integration of acquired operations and whether quarterly revenue growth can remain above the 5.9 percent rate reported for Q2 2026.